Strengthening and Expanding Synteract’s Therapeutic Expertise
We’ve seen an increasing number of studies in oncology, and general medicine, including immunology, infectious disease/vaccines, endocrine/metabolic and gastroenterology. We always want to be sure we’re offering our clients the most knowledgeable experts who bring innovative, strategic solutions to meet the demands of our rapidly evolving industry.
That’s why we’re very excited about adding three experienced leaders to Synteract. They bring a breadth and depth of knowledge in their respective therapeutic areas and a keen understanding of what is needed to move studies through the complex clinical development process.
Scott Treiber, Ph.D., MBA, VP, Strategic Development; Deb Kientop, MBA, VP, Strategic Development, Oncology; and Dr. Marie-Edith A. Bonneterre, M.D., MBA, VP, Oncology Medical Affairs, will be joining our strategic development team for the general medicine and oncology centers, as well as medical affairs respectively.
General medicine and oncology clinical trials both pose unique challenges and with the wealth of knowledge, experience, expertise, creativity, and passion that Scott, Deb, and Marie bring, Synteract will be positioned to help address the needs of our emerging biopharma customers.
Scott brings 28 years of clinical development experience to his role, having held various key leadership positions within our industry. Most recently, Scott was the chief operating officer at Elligo Health Research. Prior to that, he was executive VP, biopharmaceutical development and GM at Chiltern and held leadership roles at Theorem, inVentiv Health (now Syneos Health), ICON, and IQVIA.
Deb brings more than 25 years of experience in oncology drug development, having held a number of key leadership positions within the CRO and biopharmaceutical industry. Most recently, Deb was vice president of life sciences at Inteliquet, a healthcare technology company. Prior to that, she was a leader in oncology strategy at both ICON and IQVIA.
Marie is board certified in Medical Oncology and has over 25 years of experience in both the hospital and pharma industries, with a focus on clinical development. She was global senior medical director of Oncology drug development for PPD and served as Head of Strategic Development for Pharma Mar, as well as global medical director at the Genzyme Corporation in oncology-hematology global development. Prior to that, she was with Novartis and Sanofi.
Together, Deb, Marie, and Scott’s years of experience and expansive scientific and medical expertise will add to our already strong teams and help us continue our mission to bring clinical trials to life, so you can bring new medicines to market.
